W. Jarrard Goodwin, M.D., F.A.C.S.
Sylvester Professor, Department of Otolaryngology
Description of Research
Dr. Goodwin's research focuses on the prevention and treatment of head and neck squamous cell carcinoma (HNSCC).Cancer Prevention and Control
Dr. Goodwin has had a long-term interest in the potential of several micronutrients (selenium, retinoic acid, and beta-carotene) to inhibit the development of these cancers. Currently, various aspects of an extensive database from a Phase III chemoprevention trial, investigating the activity of beta-carotene, are being analyzed and published.
Disparities in the incidence, stage at time of diagnosis, and survival after diagnosis for underserved populations is a growing interest.
- Dr. Goodwin is currently working on a prospective study of the possible role of Vitamin D, in the disparity which negatively impacts Black Americans.
- He serves as Principal Investigator (PI) on a State of Florida, Bankhead Coley Pre-SPORE grant titled Racial Disparities and Potential New Therapeutic Strategies in Head and Neck Squamous Cell Carcinoma. This includes two projects studying genetic differences in archival tumor specimens from Black and Caucasian patients, and correlating those differences with survival.
- He serves as Miami PI in the Gulf Coast SECURE (Science, Education and Community United to Respond to Emergencies) project. This initiative was developed by a consortium of Gulf Coast Institutions to find ways to mitigate the negative impact of disasters on underserved patients with chronic diseases. It is currently supported by an NIH GO grant.
Dr. Goodwin studies the impact of treatment decisions on the quality of life experienced by patients with head and neck cancer. He published definitive outcome studies exploring the role of surgery in the multidisciplinary treatment of patients with stage IV HNSCC and recurrent HNSCC.Therapeutic Trials
Dr. Goodwin served as the local PI on a recently completed, multi-institutional, NCI-funded clinical trial studying the effect of Bowman-Birk inhibitor (a protease inhibitor) on oral leukoplakia.
He served as the local PI, and one of the most productive investigators, for Phase II and Phase III clinical trials studying the effect of P-53 gene therapy, alone and in combination with chemotherapy, for recurrent cancers of the oral cavity, pharynx, and larynx. Analysis of this work is ongoing, with the ultimate goal of receiving FDA approval.
- Established the efficacy of selenium and retinoic acid in inhibiting carcinogenesis in an animal tumor model relevant to HNSCC
- Contributed significant new knowledge regarding the role of beta-carotene, other carotenoids, and smoking cessation in the prevention of second primary head and neck cancers
- Published definitive outcome studies analyzing the results of salvage treatment for Stage IV and recurrent HNSCC
- Served as one of the leaders in the multi-institutional clinical study of P-53 gene therapy for patients with advanced and recurrent HNSCC
Selected Cancer-Related Publications
- Cheung MC, Koniaris LG, Perez EA, Molina MA, Goodwin WJ, Salloum RM. Impact of hospital volume on surgical outcome for head and neck cancer. Ann Surg Oncol 16:1001-9, 2009. Read more »
Collaborating in the Multidisciplinary Research Program(s):